Top

Naveen Pemmaraju, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Naveen Pemmaraju

After completing my Internal Medicine training at Johns Hopkins in the Osler Medical Program (2005-2008), I subsequently completed Hematology/Oncology training at MD Anderson Cancer Center Fellowship Program (MDACC; 2008-2011). I was selected as a Chief Fellow in my second year of fellowship training. I obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued my career at MDACC as an Assistant Professor in the Department of Leukemia (start date 07/2011). In September 2017, I was promoted to Associate Professor in the Department of Leukemia. I maintain an active clinical schedule, during which I see patients 2-full days per week; including 2-months of inpatient service per year. I have fellow teaching responsibilities as the Leukemia Hematology/Oncology Course Director and was the sole recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. I was recognized as our institution’s Faculty Educator of the Quarter in December 2022.

My clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML). I have authored/co-authored over 265 publications in the medical literature (all available in PubMed). I have presented our group's work, as first author, in oral presentations at numerous national/international meetings: ASCO, ASH, EHA, AACR. Under the direct mentorship of Dr. Hagop Kantarjian, and Dr. Marina Konopleva, I have established our group's first, active, BPDCN clinic; which now serves as a worldwide referral base and has brought in many new patients to MDACC. This clinic continues to expand as one of the world’s most active BPDCN research programs with dedicated infrastructure and ample support for clinical and translational studies. For these efforts, I have been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020. I am the PI/co-PI of many active clinical trials in the Leukemia department, for a translational sample study of patients with BPDCN, and was awarded a grant for identifying prognostic biomarkers in patients with BPDCN. I have developed key collaborative projects and lead groups in the areas BPDCN, MPN and AML, with clinical, hematopathology and dermatopathology teams; both internally and externally. I serve as our department’s Executive Director for the MDACC Network, helping to improve and expand upon leukemia and malignant hematology collaborations and clinical trials networking, and am an active member of the ASH Communications Committee, currently serving a 4-year term.

Meet Naveen Pemmaraju, M.D.

In the News

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Illustration of magnifying glass focused on a DNA strand

Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care

ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Medical illustration of healthy red platelets and cancerous white blood cells drifting along inside a pink-walled capillary

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

ARCHIVED: Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Present Title & Affiliation

Primary Appointment

Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

· Patients with AML and BPDCN: CD123-targeted clinical trial with SL-401. MDACC PI: Marina Konopleva, Co-PI: Naveen Pemmaraju. In this clinical trial, we and others have identified a marker present on many AML blasts, called CD123 (or IL3R alpha). Patients are offered this novel therapy with either AML, or for patients with BPDCN, a tumor in which almost all patients express high levels of CD123. This trial is open and currently enrolling patients. https://clinicaltrials.gov/ct2/show/NCT02113982

· Patients with Myelofibrosis(MF): Treatment with a Smac Mimetic, LCL-161. PI: Naveen Pemmaraju. Co-PI: Srdan Verstovsek. This is a single-institutional , Investigator-initiated phase II clinical trial. In this study, we are treating patients with a new type of targeted therapy that aims to promote cell death (apoptosis) in cancer cells, which have been found in many cases to overexpress certain proteins that prevent them from dying normally. I will be collaborating with a senior scientist in our group (Dr Bing Carter) to test all patient samples for correlative studies of the markers of cell death, to help us understand the exact nature of the drug targeting the tumor cells. This trial is currently enrolling patients. https://clinicaltrials.gov/ct2/show/NCT02098161

· Patients with Advanced Myeloproliferative Neoplams (MPNs): CMML, HES, SM, MF. Treatment with Targeted Therapy with SL-401. PI: Naveen Pemmaraju, Co-PI: Srdan Verstovsek. https://clinicaltrials.gov/ct2/show/NCT02268253

Education & Training

Degree-Granting Education

2005	University of Arkansas for Medical Sciences, Little Rock, Arkansas, US, MD
2001	Tulane University, New Orleans, Louisiana, US, Cell and Molecular Biology, BS

Postgraduate Training

2008-2011	Clinical Fellowship, Hematology and Medical Oncology, MD Anderson Cancer Center, Houston, Texas
2005-2008	Clinical Residency, Internal Medicine, Johns Hopkins Hospital, Osler Internal Medicine Program, Baltimore, Maryland

Licenses & Certifications

2012	Hematology
2011	Medical Oncology
2008	Texas State Medical License
2008	American Board of Internal Medicine

Experience & Service

Faculty Academic Appointments

Associate Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

Administrative Appointments/Responsibilities

Co-Chair, Emil J Freireich Leukemia Hematology Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present

Executive Director, Cancer Network, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Director, Cancer Network, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Hematology Consultant, Cancer Network, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022

Course Director, Leukemia Rotation, Hematology/Oncology Fellowship Program, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Co-Chair, Leukemia Hematology Grand Rounds, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2021

Other Professional Positions

Member, Patient Power Advisory Panel, USA, 2021 - 2021

Chief Fellow Housestaff Education, Hematology/Oncology, The University of Texas MD Anderson Cancer Center Fellowship Program, Houston, TX, 2009 - 2010

Extramural Institutional Committee Activities

Consultant, Medical Affairs Hematology Steering Committee 2026, Stemline Therapeutics, Inc, 2026 - Present

Member, Cancer Communications Committee for the American Society of Clinical Oncology, ASCO, 2026 - 2029

Co-Chair, Scientific Review Committee (SRC) #3, The University of Texas MD Anderson Cancer Center, 2021 - Present

Vice Chair, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Clinical Research Committee (CRC), The University of Texas MD Anderson Cancer Center, 2015 - 2021

Member, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2021

Member, Clinical Competence Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Transfusion Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2016

Member, Fellowship Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, OncoLog Editorial Board, The University of Texas MD Anderson Cancer Center, 2012 - 2017

Member, Interviewing Committee, MD Anderson Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2010 - Present

Editorial Activities

Contributing Editor, The Hematologist, 2026 - 2028

Associate Editor, Blood Cancers Today, 2022 - 2023

Editorial Board Member, Journal of Immunotherapy and Precision Oncology (JIPO), 2020 - Present

Editorial Board Chair, HemOnc Times, 2018 - 2019

Section Editor, Elsevier, 2016 - Present

Advisory Board, Oncology Times, 2016 - 2019

Staff Writer, ASH Daily News, 2016

Honors & Awards

2024	International Academy for Clinical Science 2024 Special Achievement Award, CME-Congress
2023 - 2024	Honorable Distinction, SOHO
2023 - 2024	Inducted Member, Academy of Health Science Education (AHSE), The University of Texas MD Anderson Cancer Center
2023	Faculty Educator of the Year, The University of TX MD Anderson Cancer Center
2022 - 2023	2022 MPN Hero Award, CURE, 10th Annual MPN Heroes Program
2022 - 2023	Faculty Educator of the Fourth Quarter, The University of Texas MD Anderson Cancer Center, Faculty Educator Awards Committee
2021 - 2022	Top 1% Clinical Provider Teams, The University of Texas MD Anderson Cancer Center, Physicians Referral Service and Patient Experience
2020	Gerald P. Bodey Award for Excellence in Education, The University of TX MD Anderson Cancer Center
2020	2020 Quantum Leap Award for Improving Young Adult Patient Care, Dan’s House of Hope (DHOH)
2018 - 2019	Top 10% for Exceptional Communication with Patients and Families, The University of TX MD Anderson Cancer Center
2013 - 2024	ACP Fellowship, FACP, American College of Physicians
2013 - 2014	ASH CRTI Program, American Society of Hematology
2012	M. D. Anderson Apple Award for Excellence in Patient Education, The University of TX MD Anderson Cancer Center
2011 - 2024	Advocacy Leadership Institute, American Society of Hematology
2011	Merit Award, American Society of Clinical Oncology
2010 - 2011	The Kimberly Patterson Fellowship in Leukemia Research, The University of TX MD Anderson Cancer Center
2010	Celgene 2010 Future Leaders Award for Clinical Research in Hematology, Celgene
2010	Jesse H. Jones Outstanding Teaching Fellow Award, The University of TX MD Anderson Cancer Center
2005	H. Elvin Shuffield, MD Outstanding Medical Leadership Award, University of Arkansas for Medical Sciences
2005	Elected, Class President and Student Commencement Speaker, University of Arkansas for Medical Sciences
2004 - 2005	Academic Scholarship, Arkansas Blood and Cancer Society
2004 - 2005	Academic Scholarship, Arkansas Medical Society Alliance AMA Foundation
2004 - 2005	Outstanding Geriatrics Medical Student, Junior Clerkship Award
2003 - 2004	George Link Ackerman Academic Medical Scholarship, University of Arkansas for Medical Sciences
2002 - 2003	Academic Medical Scholarship, Inaugural Class of 1957 UAMS Alumni
2000	Outstanding Peer Health Advocate of the Year, Student Crest Leadership Award

Professional Memberships

Clinical Lymphoma, Myeloma & Leukemia Editorial Board

2020 - Present

Journal of Immunotherapy and Precision Oncology (JIPO) Editorial Board

2020 - 2022

The American Society of Hematology (ASH) Committee on Communications

2020 - 2023

American Soceity of Clinical Oncology (ASCO) Cancer.Net Editorial Board

2020 - 2021

SWOG

2015 - Present

Harris County Medical Society

2013 - Present

Texas Medical Association

2013 - Present

American Association for the Advancement of Science

2012 - Present

International CML Foundation

2012 - Present

School of Science and Engineering Tulane Health Leaders Alumni Group (THLAG)

2012 - Present

Johns Hopkins Medical and Surgical Association

2012 - Present

American College of Physicians

2011 - Present

American Society for Bone and Mineral Research

2011 - 2015

American Association for Cancer Research

2010 - Present

American Society of Clinical Oncology (ASCO)

2009 - Present

American Society of Hematology (ASH)

2008 - Present

Selected Presentations & Talks

Local Presentations

2023. Lessons Learned in Studying Ultra-Rare Hematologic Malignancies: Focus on Targeting CD123 in BPDCN. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2022. co-chair, Physician Engagement Breakout Session. Conference. MD Anderson Cancer Network. Houston, TX, US.
2022. Oral Abstract | MPN-469 | Rusfertide (Ptg-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera. Conference. Society of Hematology Oncology (SOHO). Houston, TX, US.
2022. Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms. Conference. Medical Learning Institute. Houston, TX, US.
2021. Hematologic Malignancies: Pearls for the Hospitalist. Conference. The University of TX MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2025. Hepcidin Mimetics and Inducers in Polycythemia Vera. Invited. MPN-MDS US Focus Meeting 2025. Austin, Texas, US.
2025. Myeloproliferative Neoplasms in 2024 and Beyond: Clinical Pearls for the Internist. Invited. Grand Rounds - Cornell. New York, New York, US.
2023. Evolving Targets for MPN Therapy. Conference. MPN Education Foundation. Phoenix, AZ, US.
2023. A Patient Education Webinar: Live Q/A in Real Time with a Physician. Conference. MPN Advocacy and Education International. Virtual, US.
2022. Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms. Conference. 2022 Society of Hematologic Oncology (SOHO). Virtual, US.
2022. Novel Targeted Therapies for Myelofibrosis: Targeting BCLxL in MPNs. Conference. UT Health San Antonio, MD Anderson Cancer Center. San Antonio, TX, US.
2022. Opinions in the Myelofibrosis: An Interactive Local Virtual Workshop. Conference. Curio Science. Virtual, New Orleans, US.
2022. JAK Inhibitors for the Treatment of Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, Kansas, Nebraska, Oklahoma, US.
2022. Current Management and Emerging Challenges in MF. Conference. Illinois Cancer Specialists. Virtual, IL, US.
2022. Current Management and Emerging Challenges in MF. Conference. Cancer Center of Kansas. Virtual, KS, US.
2022. JAK Inhibitors for the Treatment of Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, MO, US.
2022. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, TN, US.
2021. Evolving Treatment Landscape for Cytopenic Myelofibrosis. Conference. Curio Science. Virtual, US.
2021. Myelofibrosis: Mechanism of Disease. Conference. Triptych Health Partners. Virtual, US.
2021. Panelist: Twitter. Conference. The University of TX MD Anderson Cancer Center. Virtual, TX, US.
2021. Cancer Care – Will cancer care look & feel the same way it looked pre-covid-19?. Conference. Leukemia & Lymphoma Society (LLS). Virtual, US.
2021. Panelist: Updates in AYA Tumor Management. Conference. The University of TX MD Anderson Cancer Center. Virtual, TX, US.

National Presentations

2026. Personalizing Care Across the MPN Spectrum: Risk Assessment, Treatment Strategies, and Therapeutic Transitions in PV, ET, and MF. Invited. LL&M Great Debates. Dallas, TX, US.
2026. Updates on BPDCN. Invited. AML-ALL US Focus Meeting 2026. La Jolla, CA, US.
2026. Targeting Mutant JAK2 and Mutant CALR for Therapeutic Benefit in Myelofibrosis. Invited. MPN-MDS US Focus Meeting 2026.
2026. How We Do It: A Case Presentation on the Management of Systemic Mastocytosis and Follicular Lymphoma. Invited. 23rd Annual Indy Hematology Review 2026. Indianapolis, Indiana, US.
2026. Current and Emerging Treatment Options of Blastic Plasmacytoid Dendritic Cell Neoplasm and Myeloid/Lymphoid Neoplasms with eosinophilia and Tyrosine Kinase (TK) gene fusions. 23rd Annual Indy Hematology Review 2026. Indianapolis, Indiana, US.
2026. The Emerging Landscape in Myelofibrosis. Invited. 30th Annual CFS Confrence (IHEME). Miami, FL, US.
2026. Current and Emerging Therapies in MPN (JAKi Sequencing, Novel Agents, Symptom Burden). Invited. OncLive's Bridging the Gap Leukemia Meeting. Miami, FL, US.
2025. Cases & Conversations: Real-World Insights in Advancing Management of Myelofibrosis and Polycythemia Vera – How the Experts Apply the Latest Developments in Care. Poster. American Society of Hematology (ASH). Orlando, FL, US.
2025. Clinical Updates in MPNs for 2025 And Beyond. Invited. Hematological Malignancy Research Conference. Omaha, NE, US.
2025. Rare MPNs are not so rare. Invited. MPN NYC 2025. New York City, New York, US.
2025. Next generation JAK inhibitors and promising new drugs in the MPN. Invited. 14th International Patient Symposium on MPNS. New York City, New York, US.
2025. Ruxolitinib in MF 2025: 1st JAK inhibitor approved in MF. Invited. MPN Carolinas 2025. Charlotte, North Carolina, US.
2025. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Updates for 2025. Poster. MPN Carolinas 2025. Charlotte, North Carolina, US.
2025. MF Burden, Risk and Therapy. Invited. MPN Carolinas 2025. Charlotte, North Carolina, US.
2025. Can We Modify the Disease in MF? How?. Invited. Pan Pacific Leukemia Conference 2025. Lahaina, Hawaii, US.
2025. BPDCN Highlights. Invited. AML-ALL US Focus Meeting 2025. Santa Monica, California, US.
2025. Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. Poster. American Society of Clinical Oncology (ASCO). Chicago, Illinois, US.
2025. Subgroup analysis by fitness criteria of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with first-line (1L) tagraxofusp (TAG). Poster. American Society of Clinical Oncology (ASCO). Chicago, Illinois, US.
2025. Managing MF in 2025. Invited. Joyce Niblack Memorial Conference 2025. Phoenix, AZ, US.
2025. Updates in Myeloproliferative Neoplasms. Invited. Best of Hematology. Vail, Colorado, US.
2024. Chasing Zebras: Navigating Rare Myeloid Neoplasms. Poster. American Society of Hematology (ASH). San Diego, California, US.
2024. Novel agents for the MPNs in 2024. Poster. NYC MPN 2024. New York City, New York, US.
2024. Novel agents for the MPNs in 2024. Poster. International Patient Symposium on MPNS. New York City, New York, US.
2024. Incorporating novel JAKi and other therapies in MF management. Invited. 2024 Summit on Hematological Cancers. Nashville, Tennessee, US.
2024. 13th Annual Arthur Haut M.D. Lecture. Invited. UAMS - Haut Lecture. Little Rock, Arkansas, US.
2024. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. MPN Carolinas 2024. Asheville, North Carolina, US.
2024. Novel Targeted Therapies For Myelofibrosis: Targeting BCLxL in MPNs. Invited. MPN Carolinas 2024. Asheville, North Carolina, US.
2024. BPDCN Highlights. Invited. AML-ALL US Focus Meeting 2024. San Diego, California, US.
2024. Unmet needs in MF. Invited. International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS). Boston, MA, US.
2024. Myeloproliferative Neoplasms. Invited. HemeOnc Pulse. Chicago, Illinois, US.
2024. Moving Beyond Spleen and Symptoms: Time for New Endpoints in MF?. Invited. MPN-MDS US Focus Meeting. La Jolla, California, US.
2024. BPDCN Current and Future Directions. Invited. Myeloid Malignancy Workshop. New York City, New York, US.
2024. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Reflections on the Journey of Treating an Ultra-Rare Hematologic Malignancy. Invited. Vanderbilt University Medical Center. Nashville, Tennessee, US.
2023. High Risk Myelofibrosis. Invited. Targeted Oncology. Houston, TX, US.
2023. Current management paradigm in MF: Standard of Care. Invited. APTITUDE Health, US.
2023. Risk Stratifying Patients With ET. Invited. MJH Life Sciences. Virtual, US.
2023. BPDCN Case Presentation. Invited. APTITUDE Health, Targeted Oncology. Virtual, TX, US.
2023. Myeloproliferative Neoplasms Including Chronic Myeloid Leukemia. Invited. American Society of Hematology (ASH). San Francisco, CA, US.
2022. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort. Conference. American Society of Hematology (ASH). New Orleans, LA, US.
2022. Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera. Invited. American Society of Hematology (ASH). New Orleans, LA, US.
2022. Identifying and Managing Patients with BPDCN: Practical Insights from the Multidisciplinary Team. Invited. Medscape, Menarini. New Orleans, LA, US.
2022. Tagraxofusp, a CD123-directed Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial. Conference. American Society of Hematology (ASH). New Orleans, LA, US.
2022. A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage. Conference. American Society of Hematology (ASH). New Orleans, LA, US.
2022. Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy. Invited. Physicians Education Resource, LLC. New Orleans, LA, US.
2022. Beware of toxicities, complications to monitor for as we enter combination era. Invited. MJH Life Sciences. Virtual.
2022. How to build and maintain a rare disease clinical and research program. Invited. 1st Congress on Myeloproliferative Neoplasms Controversies and Debates (MPNCo&D). Virtual.
2022. Anemia in MF: emerging area for novel approaches. Invited. GSK. Virtual.
2022. Debate: Novel therapies in combinations in MF: an emerging new era: With JAKi – important steps forward in patient management. Invited. 1st Congress on Myeloproliferative Neoplasms Controversies and Debates (MPNCo&D). Virtual.
2022. Updates in the Management of Polycythemia Vera (PV). Invited. Bio Ascend. Virtual, US.
2022. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Invited. American Association for Cancer Reserach (AACR). New Orleans, LA, US.
2022. Approach to Diagnosis and Treatment of BPDCN. Invited. Great Debates & Updates in Hematologic Malignancies. Virtual, US.
2022. Navitoclax and Bcl-xL in Myelofibrosis. Invited. DAVA Oncology. Amelia Island, FL, US.
2022. Management of Myelofibrosis in the 2020s: Exciting Targets on the Horizon. Invited. DAVA Oncology. Amelia Island, FL, US.
2022. Moderator: Perspectives on ASH 2021 - An Expert Discussion. Invited. Journal of Immunotherapy and Precision Oncology. Virtual, US.
2021. Novel targeted agents in clinical trials for MPN. Invited. Alpine Oncology Foundation. Virtual, US.
2021. Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Atlanta, GA, US.
2021. Completely Beyond JAKi (CD123 with SL401). Invited. Remedy Health Media. Virtual, US.
2021. Current Data on Navitoclax: Targeting BCL-2/BCL-xL in Myelofibrosis. Invited. Dave Oncology. Virtual, US.
2021. Navitoclax mechanism and Refine phase 2 data. Invited. AbbVie. Virtual, US.
2021. JAKi therapy and other emerging novel therapies for myelofibrosis. Invited. BinayTara Foundation. Virtual, UT, US.
2021. Advances In CAR T-Cell Therapy. Invited. Leukemia and Lymphoma Society (LLS). Virtual, US.
2021. Case Presentations in Myelofibrosis (MF). Invited. Physicians’ Education Resource, LLC (PER). Virtual, US.
2021. Toxicity Mitigation in CML Therapy. Invited. Imedex. Virtual, US.
2021. Novel Therapies for MPNs with a Focus on CMMoL. Invited. Imedex. Virtual, US.
2021. Poster #150: Outcomes of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Who Received Hematopoietic Stem Cell Transplantation Following Remission Induction with Tagraxofusp, a Targeted Therapy Directed to CD123. Conference. Stemline Therapeutics. Virtual, US.
2020. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Conference. 62nd ASH Annual Meeting & Exposition. Virtual, US.
2020. The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. Conference. 62nd ASH Annual Meeting & Exposition. Virtual, US.
2020. Current and Emerging Strategies for BPDCN. Invited. 38th Annual Chemotherapy Foundation Symposium (CFS): Innovative Cancer Therapy for Tomorrow. Virtual, US.
2020. Rare Diseases: Blastic Plasmacytoid Dendritic Cell Neoplasm. Invited. Imedex. Virtual, US.
2020. Novel Agents in MPN Beyond JAK inhibitors. Invited. Alpine Oncology Foundation. Virtual, US.
2020. Case Studies in Blastic Plasmacytoid Dendritic Cell Neoplasm: Tackling the Diagnostic Challenge. Invited. Stemline Therapeutics. Virtual, US.
2020. Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial. Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2020. Updated Results from a Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Myelofibrosis. Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2020. Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML). Conference. Society of Hematologic Oncology (SOHO). Houston, TX, US.
2020. Treatment of Chronic Idiopathic Myelofibrosis. Invited. Imedex. New York, NY, US.
2020. Treatment Approach for Aggressive Myeloproliferative Neoplasms. Conference. Imedex. New York, NY, US.
2020. Session VIII: Q&A Keynote: How has the pandemic affected treatment of Hemotologic Malignancies in NY?. Conference. Imedex. New York, NY, US.
2020. What is the Main Objective of Therapy in CML? Improve Survival Endpoints. Invited. Imedex. New York, NY, US.
2020. Therapeutic Landscape of MPN and MDS: What to Do After Ruxolitinib Failure. Invited. DAVA Oncology, (OMI) Oncology Meeting Innovations. Irving, TX, US.
2020. Updates and Novel Therapies in BPDCN. Invited. University of Miami Health System, Sylvester Comprehensive Cancer Center. Miami, FL, US.
2019. Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing Patients’ Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Information Era. Conference. American Society of Hematology (ASH). Orlando, FL, US.
2019. Data on Treatment Options for Myelofibrosis. Invited. Amerisource Bergen. San Francisco, CA, US.
2019. Chronic Myeloid Leukemia (CML). Invited. Leukemia & Lymphoma Society. San Antonio, TX, US.
2019. ASH Committee on Communications. Invited. ASH Committee, WA, US.
2016. Outcome of Patients with Philadelphia Chromosome-Negative Acue Lymphoblastic Leukemia (ALL) By Age Group of er 35 Years: A Single Institution Experience. Conference. Outcome of Patients with Philadelphia Chromosome-Negative Acue Lymphoblastic Leukemia (ALL) By Age Group of er 35 Years: A Single Institution Experience. San Diego, CA, US.
2016. Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Conference. ASH 2016 Annual Meeting. San Diego, CA, US.
2014. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Invited. 56th Annual Meeting American Society of Hematology. San Francisco, CA, US.
2011. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia, oral presentation. Invited. 2011 Chronic Lymphocytic Leukemia Young Investigators' Meeting. Houston, TX, US.
2011. Dasatinib as initial therapy for patients with chronic myeloid leukemia in early chronic phase, oral presentation. Invited. Mini-Symposia American Association for Cancer Research. Orlando, FL, US.
2010. Retrospective review of male breast cancer patients: analysis of tamoxifen-relted side effects, poster presentation. Conference. 33rd Annual Meeting San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2008. A green apple in the chest: amyloidosis, poster presentation. Conference. 31st Annual Meeting Society of General Internal Medicine. Pittsburgh, PA, US.
2008. Overactive bladder, underactive bowel: solifenacin-associated small bowel pseudo-obstruction, poster presentation. Conference. Society of Hospital Medicine Annual Meeting. San Diego, CA, US.
2006. Heterogeneous JAK2V617F allele burden in essential thrombocytosis: gender and clinical correlates, oral presentation. Invited. 48th Annual Meeting American Society of Hematology. Orlando, FL, US.
2005. Osler's aequanimitas in the twenty-first century, oral presentation. Invited. 7th Annual Meeting of Southern Association for History of Medicine and Sciences. Atlanta, GA, US.

International Presentations

2026. BPCDN Updates. Invited. Pan-Hematology Clinical Meeting 2026. San Juan, US.
2025. Focus on rare hematologic malignancies: pearls and reflections. Invited. International Academy for Clinical Hematology (IACH). Paris, FR.
2025. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Targeting CD123. Invited. iwAL 2025. Washington, D.C, US.
2025. EFFICACY AND SAFETY OF PIVEKIMAB SUNIRINE (PVEK) IN PATIENTS (PTS) WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) IN THE CADENZA STUDY. Poster. European Hematology Association (EHA). Milan, IT.
2024. Review of JAKi in treatment of MF which drug when to use. Poster. International Academy for Clinical Hematology (IACH). Paris, FR.
2024. BH3 mimetics for myeloid malignancies. Invited. International Society for Experimental Hematology (ISEH). Chicago, US.
2024. “EFFICACY AND SAFETY OF NAVITOCLAX IN COMBINATION WITH RUXOLITINIB VERSUS RUXOLITINIB PLUS PLACEBO IN PATIENTS WITH UNTREATED MYELOFIBROSIS IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND TRANSFORM-1 STUDY. Poster. European Hematology Association (EHA). Madrid, ES.
2024. Blastic plasmacytoid dendritic cell neoplasm. Invited. India Leukemia Academy. Faridabad, Haryana, IN.
2023. Updates in diagnosis, pathogenesis, and future directions in BPDCN. Invited. VJHemeOnc. San Diego, US.
2023. Bench to bedside in MPNs – 10 years of CALR. Invited. VJHemeOnc. San Diego, US.
2023. INTERIM ANALYSIS OF A REGISTRATION-ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN). Invited. European Hematology Association (EHA). Frankfurt, DE.
2023. Advances in Myelofibrosis: Exploring the Current and Evolving Treatment Landscape. Invited. Bristol Myers Squibb. Frankfurt, DE.
2023. Adolescents and Young Adults with Hematologic Malignancies: Patient Characteristics and Special Considerations. Invited. American Society of Clinical Oncology (ASCO). Chicago, US.
2023. Advances in the Diagnosis and Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Saudi Society of Bone Marrow Transplantation (SSBMT). Riyadh, SA.
2023. Updates in Myeloproliferative Neoplasms. Invited. The ASCO Post. Virtual, US.
2023. Targeting CD123 in BPDCN. Invited. DAVA Oncology. Whistler, CA.
2023. Novel approaches to the treatment of myeloproliferative neoplasms. Invited. DAVA Oncology. Whistler, CA.
2023. MRD evaluation of AML in clinical practice, Is it ready and how to assess?. Invited. Emirates Medical Association. Virtual, GB.
2023. Using precision medicine to treat AML in 2023. Invited. Emirates Medical Association. Virtual, AE.
2023. How I treat Blastic Plasmacyyoid Dendretic Cell Neoplasm (BPDCN). Invited. Emirates Haematology Conference 2023. Virtual, AE.
2023. Evolving Diagnostic and Therapeutic Approaches in BPDCN. Invited. Menarini-UAE, SA.
2023. Combination Approaches for Myelofibrosis. Invited. Hôpital Saint Louis. Berlin, DE.
2023. Standard and novel therapies in MPN MYELOFIBROSIS Around the World. Invited. Philippine College of Hematology and Transfusion Medicine (PCHTM). Virtual, PH.
2022. Medical Session #4: Personalized medicine in MPNs - Oxford style debate: Late-stage Myelofibrosis. Transplant or not? No. Invited. MPN Advocates Network. Netanya, IL.
2022. Medical Session 2: Novel Therapies in MPNs - Past and Future of MPN Treatment. Invited. MPN Advocates Network. Netanya, IL.
2022. Medical Session 1: Challenges still exist in MPNs: Diagnosing MPNs. Invited. MPN Advocates Network. Netanya, IL.
2022. Combining Novel Agents for Treating Myelofibrosis. Invited. Melton Medical Education. Brooklyn, US.
2022. Pivekimab efficacy data from the AML triplet (802) and BPDCN (801) studies. Invited. Immunogen, Inc. Rome, IT.
2022. How I manage BPDCN in MDACC. Invited. SOHO Italy: 2022 Annual Conference Hybrid Event. Rome, IT.
2022. Tagraxofusp in 2022: State of the Art. Conference. Stemline Therapeutics. Rome, IT.
2022. A revolution in ultra-rare diseases: the example of BPDCN. Invited. 5th Annual Meeting of the International Academy for Clinical Hematology (IACH). Virtual, FR.
2022. RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS. Invited. CTI Biopharma, European Hematology Association (EHA). Virtual, Vienna, AT.
2022. TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY. Invited. European Hematology Association (EHA). Virtual, Vienna, AT.
2022. Placing New MPN Therapies into Context Through Illustrated Case Discussions. Invited. Physician's Education Resource (PER). Chicago, US.
2022. Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF). Invited. American Society of Clinical Oncology (ASCO). Chicago, US.
2022. CONTROVERSIES IN MYELOFIBROSIS: DEFINING AND MEASURING DISEASE MODIFICATION. Invited. AbbVie. Virtual, Budapest, HU.
2022. Moderator for Q&A: Patient Case Presentations. Invited. Novartis. Virtual, Karel V, Utrecht, NL.
2022. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Invited. The International Academy for Clinical Hematology (IACH). Virtual.
2022. Tagresofusp, BPDCN and its management. Invited. Stemline, Astellas. Virtual, GB.
2022. Co-Chair: Session 1 – SCIENCE ADVANCES IN THE MPN FIELD. Invited. Magdelen Medical Publishing. Virtual, US.
2022. Co-Chair: Session 4 - OPEN STUDIES. Invited. Magdelen Medical Publishing. Virtual, US.
2021. Clinical Management for BPDCN. Invited. Physicians' Education Resource, LLC (PER), MJH Life Sciences, Stemline Therapeutics, Inc. Virtual, US.
2021. Chronic MPN (Myeloproliferative Neoplasms) Update. Invited. Cleveland Clinic & Aplastic Anemia and MDS International Foundation, Friday Satellite Symposia: Resuscitating a Dying Marrow: Emerging Concepts and Treatment Advances in Myeloid Malignancies. Atlanta, US.
2021. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Fondazione Internazionale Menarini, CONTATTO & ARCHIMEDICA Edizioni Scientifiche. Virtual, IT.
2021. New agents of potential value in the MPN. Invited. Melton Medical Education, LLC. Virtual, US.
2021. Co-Chair, Myelofibrosis External Experts Advisory Roundtable. Conference. CTI BioPharma. Virtual, US.
2021. How I manage BPDCN at MD Anderson Cancer Center. Invited. Society of Hematologic Oncology (SOHO) Italy. Virtual, IT.
2021. Taking the torch from discoverers: bring forth hope to hopeless patients with devastating neoplasms such as BPDCN. Invited. Society of Hematologic Oncology (SOHO) Italy, Stemline Therapeutics Switzerland GmbH. Virtual, IT.
2021. Quality of Life. Invited. Canadian Myeloproliferative Neoplasm (MPN) Network. Virtual, CA.
2021. BPDCN. Invited. International Academy for Clinical Hematology (IACH). Virtual, FR.
2021. Using and Sequencing JAK Inhibitors for Patients with Myelofibrosis. Invited. Bio Ascend. Virtual, US.
2021. Novel Treatment Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Neopharm Israel. Virtual, IL.
2021. Novel insights into the biology and treatments of blastic plasmacytoid dendritic cell neoplasm. Invited. Menarini-Stemline. Virtual, NL.
2021. Navitoclax and Ruxolitinib Combination in Patients with Myelofibrosis. Invited. Bristol Myers Squibb. Virtual, NL.
2021. CD123-Targeting Antibody Drug Conjugate (ADC) Monotherapy for Blastic Plasmacytoid Dendritic Cell Neopalsm (BPDCN). Invited. DAVA Oncology. Virtual, CA.
2021. How I Treat Myelofibrosis (MF) in Lower/Intermediate Risk Patients. Invited. NOVARTIS. Virtual, CO.
2021. Meet the Expert Session – How to safely and successfully use social media in medicine. Invited. European School of Hematology (ESH). Virtual, FR.
2021. Interactive case: Blastic plasmacytoid dendritic cell neoplasms. Invited. European School of Hematology (ESH). Virtual, FR.
2021. Session IV, Novel Therapies in AML & BPDCN: Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. The Scientific Committee of the International Workshop on Acute Leukemias (iwAL). Virtual, US.

Formal Peers

2023. Chronic Myeloid Leukemia (CML) 101. Visiting. Houston, TX, US.
2023. Introduction to Myeloproliferative Neoplasms (MPNs) 101. Visiting. Houston, TX, US.
2023. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in 2023 and Beyond: Lessons Learned from Investigating an Ultra-Rare Hematology Malignancy. Visiting. Salt Lake City, UT, US.
2023. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in 2023 and Beyond: Lessons Learned from Investigating an Ultra-Rare Hematology Malignancy. Visiting. New York, NY, US.
2023. Case Conference with Dr. Dillard and Dr. Pemmaraju - BPDCN. Visiting. Houston, TX, US.
2022. Novel Therapeutic Combinations in Myelofibrosis: Focus on Targeting BCLxL in MPNs and Beyond. Visiting. Houston, TX, US.
2022. Chronic Myeloid Leukemia (CML) 101. Visiting. Houston, TX, US.
2022. Introduction to Myeloproliferative Neoplasms (MPNs): MPN 101. Visiting. Houston, TX, US.
2022. Blastic Phasmacytoid Dendritic Cell Neoplasm (BPDCN): Updates and Future Directions for 2022 & Beyond. Visiting. Houston, TX, US.
2022. BPDCN. Visiting. Aurora, CO, US.
2022. Targeting BCL-xL with Navitoclax in Myelofibrosis: An Emerging Area. Visiting. Houston, TX, US.
2022. Focusing on An Ultra-Rare Disease: Lessons Learned in Development of Novel Approaches for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Visiting. Virtual, US.
2022. Introduction to BPDCN diagnosis, treatment, and management. Visiting. Houston, TX, US.
2021. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Lessons learned from studying and ultra-rare disease. Invited. Virtual, MI, US.
2021. Resident and Fellows Lecture: BPDCN. Invited. Virtual, IN.
2021. Mortality and Morbidity Case Study. Visiting. Houston, TX, US.
2021. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Visiting. Houston, TX, US.
2021. Grand Rounds for Fred Hutch: Novel Therapeutic Approaches in Blastic Plasmcytoid Dendritic Cell Neoplasm (BPDCN): Targeting CD123 and Beyond. Invited. Virtual, WA, US.
2021. RUXO + Navitoclax/BCLXL in MPN. Visiting. Houston, TX, US.
2020. Chronic Myeloid Leukemia (CML). Visiting. Houston, TX, US.
2020. Introduction to Myeloproliferative Neoplasms (MPNs): MPN 101. Visiting. Houston, TX, US.
2020. Novel Therapies and Future Directions in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Iowa City, IA, US.
2020. Novel Therapies and Future Directions in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Invited. Denver, CO, US.
2019. Levine Cancer Institute Grand Rounds: Updates and Developments in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - State of the Art for 2020 and Beyond. Invited. Charlotte, NC, US.
2019. Medical Grand Rounds: Novel Agents Beyond JAK inhibitors in Treatment of Patients with MPNs. Invited. Durham, NC, US.
2019. Medical Grand Rounds: Updates and Developments in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - State of the Art for 2020 and Beyond. Invited. Buffalo, NY, US.
2019. Updates and Progress in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in the Era of Novel/Targeted Therapies in 2019 and Beyond. Invited. Miami, FL, US.
2019. Cancer Center Grand Rounds: BPDCN - Era of Targeted Therapy in 2019 and Beyond. Invited. Phoenix, AZ, US.
2016. State of the Art: Update for BPDCN in 2016. Visiting. Houston, TX, US.
2010. Outcomes with FLT3 inhibitors: personalized targeted therapy for acute myeloid leukemia. Visiting. Houston, TX, US.
2010. Hematology/Oncology Board Review Series (3 lectures). Invited. Houston, TX, US.

Less

Grant & Contract Support

Date:	2023 - Present
Title:	A phase 1b study of ABBV-744 alone or in combination with Ruxolitinib or Navitoclax in subjects with myelofibrosis
Funding Source:	AbbVie
Role:	PI
ID:	2022-1084

Date:	2022 - 2024
Title:	Phase 1 Evaluation of the Safety and Pharmacokinetics of First-in-class N-myristoylation Inhibitor, PCLX-001, in Patients with Relapsed/Refractory Acute Myeloid
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	FP#14594

Date:	2022 - 2039
Title:	A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients with Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, and High Risk Myelodysplastic Syndrome
Funding Source:	MustangBio, Inc
Role:	PI
ID:	2019-0097 / MB102-CD123-001

Date:	2022 - 2036
Title:	A Long-term Follow-up Study in Patients Previously Treated with Mustang Bio, Inc. CAR-T Cell Investigational Products
Funding Source:	MustangBio, Inc
Role:	PI
ID:	2021-0314 / MB100-OBS-001

Date:	2021 - 2025
Title:	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Funding Source:	AbbVie
Role:	PI
ID:	2020-0743 / M16-191

Date:	2020 - 2027
Title:	Telios Pharma, Inc
Funding Source:	Telios Pharma, Inc
Role:	PI
ID:	2020-0738

Date:	2020 - 2024
Title:	Identifying Novel Therapeutic Targets and Combination Strategies for Patients with BPDCN
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	W81XWH2010683 / USAMRAA

Date:	2020 - 2026
Title:	Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): SL-401 in combination with HCVAD and VENETOCLAX
Funding Source:	Stemline Therapeutics, Inc. / UT MD Anderson Cancer Center
Role:	PI
ID:	2019-0587

Date:	2015 - 2027
Title:	A Study to Evaluate Patient Samples with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Funding Source:	Cellectis S.A., Moonshots Program, Affymetrix, Inc
Role:	PI
ID:	PA14-0157

Selected Publications

Peer-Reviewed Articles

Pemmaraju N, Markova A, Masarova L, Reaven N, Funk SE, Ferguson TW, Bellamy LA, Dinh P, Oyuela P, Valone F, Molina A, Gupta S. Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: A real-world study. Blood Adv 10(13):4860-4871, 2026. e-Pub 2026. PMID: 42054546.
Lane AA, Luskin MR, Keating JH, LeBoeuf NR, Garcia JS, Shimony S, Leonard R, Goodpaster A, Nguyen T, Galinsky I, Eberly Puleo A, Daver NG, Jain N, Garcia-Manero G, Kantarjian HM, Konopleva M, Stein AS, Pemmaraju N. Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2026. e-Pub 2026. PMID: 42413008.
Beird HC, Kannan S, Liu J, Chen J, Olguin A, Desai P, Cai T, Han L, Cotton JL, Singh S, Gupta SK, Little L, Estecio MR, Song X, Abbas HA, Zhang J, Gumbs C, Brooks C, Kantarjian H, Andreeff M, Konopleva M, Futreal P, Pemmaraju N. Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II. Leukemia. e-Pub 2026.
Beird HC, Kannan S, Liu J, Chen J, Olguin A, Desai P, Cai T, Han L, Cotton JL, Singh S, Gupta SK, Little L, Estecio MR, Song X, Abbas HA, Zhang J, Gumbs C, Brooks C, Kantarjian H, Andreeff M, Konopleva M, Futreal PA, Pemmaraju N. Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II. Leukemia, 2026. e-Pub 2026. PMID: 42410207.
Pemmaraju N, Herling M, Sweet KL, Stein AS, Vasu S, Rosenblat TL, Rizzieri DA, Papayannidis C, Wang ES, Konopleva M, Zuurman M, Tosolini A, Qazilbash M, Lane AA. First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level. Haematologica 111(7):2508-2513, 2026. e-Pub 2026. PMID: 41537340.
Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 101(7):1737-1747, 2026. e-Pub 2026. PMID: 42035228.
Lane AA, Luskin MR, Keating JH, LeBoeuf NR, Garcia JS, Shimony S, Leonard R, Goodpaster A, Nguyen T, Galinsky I, Puleo AE, Daver NG, Jain N, Garcia-Manero G, Kantarjian HM, Konopleva M, Stein AS, Pemmaraju N. Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood. e-Pub 2026.
Pemmaraju N, Lucchesi A, Oh ST, Wilson K, Hakimi Z, Buckley SA, Suthar P, Parkitny M, Wojciechowski P, Kolonko K, Mascarenhas JO. Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison. Expert Rev Hematol:1-9, 2026. e-Pub 2026. PMID: 42316774.
Pemmaraju N, Mead AJ, P Somervaille TC, Palandri F, Koschmieder S, Delage R, Kiladjian J, Benton CB, Tantravahi SK, Lavi N, Yeh S, Gomez Casares MT, Ammatuna E, McDonald AB, Yoon S, Kirito K, Devos T, Perkins AC, Radinoff A, Sevindik OG, Bogdanovic A, Moskal R, Harb JG, Murray BC, Jiang Q, Chopra AS, Papadopoulos EJ, Potluri J, Passamonti F. TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Blood. e-Pub 2026.
Pemmaraju N, Mead AJ, Somervaille TCP, Palandri F, Koschmieder S, Delage R, Kiladjian JJ, Benton CB, Tantravahi SK, Lavi N, Yeh SP, Gomez Casares MT, Ammatuna E, McDonald AB, Yoon SS, Kirito K, Devos T, Perkins AC, Radinoff A, Sevindik OG, Bogdanovic A, Moskal R, Harb JG, Murray BC, Jiang Q, Chopra AS, Papadopoulos EJ, Potluri J, Passamonti F. TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Blood, 2026. e-Pub 2026. PMID: 42378247.
Swaminathan M, Abbas HA, Roth M, Hildebrandt MAT, Fingrut W, Kadia T, Daver N, DiNardo C, Borthakur G, Jabbour E, Pemmaraju N, Alvarado Y, Ohanian M, Jain N, Short N, Bose P, Takahashi K, Pierce S, Hwang H, Huang X, Edelkamp P, Kebriaei P, Popat U, Shpall E, Garcia-Manero G, Ravandi F. Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk, 2026. e-Pub 2026. PMID: 42469064.
Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG. Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. J Hematol Oncol, 2026. e-Pub 2026. PMID: 42304430.
Singh A, Daver N, Loghavi S, Kadia T, Ravandi F, DiNardo C, Borthakur G, Pierce S, Futreal A, Aung PP, Cuglievan B, Jain N, Jabbour E, Garcia-Manero G, Konopleva M, Qazilbash M, Pemmaraju N. Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma 67(7):1616-1619, 2026. e-Pub 2026. PMID: 41711093.
Marvin-Peek J, DiNardo CD, Loghavi S, Ravandi F, Borthakur G, Daver NG, Kadia TM, Jabbour E, Dunbar A, Tang G, Short NJ, Haddad FG, Abbas HA, Kugler E, Maiti A, Issa GC, Takahashi K, Bhalla K, Pemmaraju N, Alvarado Y, Shpall EJ, Popat U, Ramdial J, Champlin RE, Kantarjian HM, Garcia-Manero G, Senapati J. Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. Cancer 132(10):e70434, 2026. e-Pub 2026. PMID: 42089434.
Khanlari M, Nunez MT, Maciaszek JL, Eldomery MK, Wang W, Cheng Z, Myers J, Jones KD, Gheorghe G, Key L, Liu YC, Barceiro R, Pena A, Castellino S, Rosado RE, E Sousa MB, Bledsoe JR, Pemmaraju N, Klco JM, Ribeiro RC. Pediatric blastic plasmacytoid dendritic cell neoplasms are molecularly defined by recurrent MYB rearrangements: clinical and molecular insights. Haematologica, 2026. e-Pub 2026. PMID: 42095245.
Montalban-Bravo G, Wu C, Rodriguez-Sevilla JJ, Wei Y, Chien KS, Bouligny I, Kanagal-Shamanna R, Li Z, Natu A, Gurney M, Bazinet A, Hammond D, Bataller A, Borthakur G, Short NJ, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Jabbour E, Issa GC, Wang SA, Patel KP, Tang G, Medeiros LJ, Lasho TL, Finke CM, Al-Kali A, Csizmar CM, Alkhateeb H, Gangat N, Mangaonkar AA, Roman-Bravo D, Arenillas L, Tefferi A, Kantarjian HM, Garcia-Manero G, Calvo X, Patnaik MM, Loghavi S. Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia. Blood Cancer Discov 7(3):414-430, 2026. e-Pub 2026. PMID: 41587375.
Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, Estrov Z, Bharathi V, Bataller A, Kadia TM, Pemmaraju N, Daver N, Jabbour E, Bose P, Kanagal-Shamanna R, Patel KP, Wang SA, Garg N, Hwang H, Wang X, Qiao W, Xu X, Cruz N, Ayala A, Pierce S, Plunkett W, Sampath D, Kantarjian HM, Keating MJ, Gandhi V, Wierda WG, Jain N. Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Blood Cancer Discov 7(3):431-440, 2026. e-Pub 2026. PMID: 41678768.
Haddad FG, Jabbour E, Sasaki K, Black S, Savoy JM, Alvarado Y, Borthakur G, Pemmaraju N, Yilmaz M, Delasalla S, Issa GC, Kantarjian H. Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis. Clin Lymphoma Myeloma Leuk 26(5):e678-e682.e1, 2026. e-Pub 2026. PMID: 41876352.
Ali, HR, Faiz, S, Deswal, A, Palaskas, NL, Iliescu, C, Thompson, KA, Ohanian, M, Pemmaraju, N, Bose, P, Sahay, S. Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension. JACC: CardioOncology 8(2):200-204, 2026. e-Pub 2026. PMID: 41910516.
Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol 44(10):861-873, 2026. e-Pub 2026. PMID: 41671533.
Pemmaraju N, Konopleva M, Qazilbash M, Stein AS, Rizzieri DA, Wang ES, Vasu S, Gupta I, Lane AA. Durable post-transplant survival after first-line tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma 67(5):1172-1176, 2026. e-Pub 2026. PMID: 41404717.
Bazinet A, Bataller A, Chien K, Sasaki K, Montalban-Bravo G, Hammond D, Bouligny I, Swaminathan M, Jen WY, Kugler E, Kanagal-Shamanna R, Kadia T, Borthakur G, DiNardo C, Short N, Pemmaraju N, Jabbour E, Daver N, Ravandi F, Urrutia S, Gener-Ricos G, Braish J, Briski R, Rodriguez-Sevilla JJ, Li Z, Champlin RE, Shpall EJ, Alousi A, Oran B, Hosing C, Ramdial JL, Olson A, Pierce S, Chen J, Kantarjian H, Garcia-Manero G, Popat U. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. Blood Cancer J 16(1), 2026. e-Pub 2026. PMID: 41896225.
Ali HR, Faiz SA, Deswal A, Palaskas N, Iliescu C, Thompson K, Ohanian M, Pemmaraju N, Bose P, Sahay S. Sotatercept for the Treatment of Myeloproliferative Neoplasm-Associated Group 5 Pulmonary Hypertension. JACC CardioOncol, 2026. e-Pub 2026. PMID: 41910516.
Wei Q, Pemmaraju N, Wang SA, Hu S, Dinardo C, Issa GC, Bueso-Ramos CE, Xu J, Li S, Medeiros LJ, Tang G. Acute myeloid leukemia with t(10;17)(p15;q21)/ ZMYND11::MBTD1: a subtype with minimal differentiation, CD7/CD56 expression, and generally poor outcomes in adults. Haematologica 111(3):1130-1135, 2026. e-Pub 2026. PMID: 41262054.
Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA. Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer 132(1):e70243, 2026. e-Pub 2026. PMID: 41486505.
Mohty, M, Savani, BN, Bazarbachi, A, Blaise, D, Huang, H, Malard, F, Kharfan-Dabaja, MA, Facon, T, Brissot, E, Perić, Z, Ruggeri, A, Zeidan, AM, Pemmaraju, N, Shoham, Z, Melo, JV, Nagler, A. The International Academy for Clinical Hematology (IACH) 2026–2030 strategic vision and roadmap. Clinical Hematology International 8(2):59-62, 2026. e-Pub 2026.
Bharathi V, Jen WY, Venugopal S, Thakral B, Daver N, Chien K, Bose P, Masarova L, Pemmaraju N, Tang G, Jain N. Durable complete remission with imatinib monotherapy in a patient with FIP1L1-PDGFRA rearranged myeloid neoplasm with extramedullary involvement. Leuk Lymphoma 67(1):225-228, 2026. e-Pub 2026. PMID: 41194520.
Nanduri AC, Ashraf F, Hlaing SS, Brister M, Kadia TM, Pemmaraju N, Budak-Alpdogan T. Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass. Acta Haematol 149(2):221-227, 2026. e-Pub 2026. PMID: 40159328.
Sabitha P, Goel A, Kumar S, R C, Fernandes S, Jain N, Pemmaraju N, Sharma A, Sahoo RK. Blastic plasmacytoid dendritic cell neoplasm: A single centre Indian experience. Leuk Res Rep 25:100560, 2026. e-Pub 2026. PMID: 41890270.
Voskanyan A, Badikyan M, Konopleva M, Alencar A, Ivanyan A, Owen C, Sergi CM, Peng CT, Kazandjian D, Taylor J, Tekkesin F, Ghali H, Bedirian K, Martelli MP, Attardi E, Voso MT, Abramashvili M, Al-Jadiry MF, Michael M, Su MY, Martirosyan N, Ghahramanyan N, Totogashvili N, Kotoucek PP, Kebudi R, Ohannessian R, Papyan R, Hovsepyan S, Elashwah S, Bakhshi S, Bardakhchyan S, Danelyan S, El-Ashwah S, Kutluk T, Tugcu D, Alhuraiji A, Lazaris V, Tamamyan G, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program. Discov Oncol 16(1):2211, 2025. e-Pub 2025. PMID: 41422449.
Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
Stein AS, Lane AA, Sweet KL, Vasu S, Tosolini A, Katsetos J, Konopleva M, Pemmaraju N. First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. Br J Haematol 207(6):2592-2596, 2025. e-Pub 2025. PMID: 41077812.
Goulart H, Ravandi F, Short NJ, Jain N, Daver N, Kadia TM, DiNardo C, Borthakur G, Takahashi K, Pemmaraju N, Haddad FG, Montalban Bravo G, Alvarado Y, Issa GC, Bataller A, Pierce S, Loghavi S, Tang G, Wang SA, Thakral B, Shpall E, Champlin R, Khouri I, Kebriaei P, Garcia-Manero G, Sasaki K, Jabbour EJ, Senapati J. Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. JCO Precis Oncol 9:e2500494, 2025. e-Pub 2025. PMID: 41370732.
Senapati J, Konopleva M, Issa GC, Jabbour E, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Short NJ, Yilmaz M, Deshmukh I, Alvarez J, Loghavi S, Tang G, Abbas HA, Andreeff M, Bhalla K, Midde NM, Said N, Noyalis A, Mires DE, Ning J, Xiao L, Ravandi F, Garcia-Manero G, Kantarjian HM, Daver NG. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias. J Hematol Oncol 18(1):108, 2025. e-Pub 2025. PMID: 41310838.
Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv 9(21):5598-5609, 2025. e-Pub 2025. PMID: 40829105.
Goulart H, Jabbour E, Short NJ, Kadia TM, Pemmaraju N, Takahashi K, Ravandi F, Konopleva M, Jain N. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 25(11):800-807, 2025. e-Pub 2025. PMID: 40500616.
Croden J, Pemmaraju N, Fliehler K, Brown A, Wang W, Kantarjian H, Vega F, Kadia T. Managing BPDCN in the context of severe hyperbilirubinemia: a case study. Leuk Lymphoma 66(11):2139-2142, 2025. e-Pub 2025. PMID: 40569706.
DiNardo CD, Jen WY, Montalban-Bravo G, Wang X, Loghavi S, Lavu S, Short NJ, Chien K, Issa GC, Pemmaraju N, Yilmaz M, Andreeff M, Borthakur G, Kadia TM, Daver NG, Garcia-Manero G, Mill CP, Su X, Fiskus W, Bhalla KN. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4):100145, 2025. e-Pub 2025. PMID: 40979071.
Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, Schiller GJ, Stevens DA, Talpaz M, Wall S, Lasho TL, Mangaonkar AA, Badar T, Lindsay R, Galleu A, Gupta I, Pemmaraju N, Garcia-Manero G. Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. Blood Neoplasia 2(4):100115, 2025. e-Pub 2025. PMID: 40919483.
Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N. Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. Blood Neoplasia 2(4):100165, 2025. e-Pub 2025. PMID: 41146971.
Montalban-Bravo G, Loghavi S, Li Z, Chien K, Kanagal-Shamanna R, Bataller A, Natu A, Gurney M, Bazinet A, Hammond D, Sasaki K, Borthakur G, Swaminathan M, DiNardo C, Kadia T, Ravandi F, Daver N, Short N, Pemmaraju N, Issa G, Lasho TL, Finke CM, Al-Kali A, Csizmar C, Alkhateeb H, Gangat N, Mangaonkar AA, Bueso-Ramos C, Tefferi A, Kantarjian H, Garcia-Manero G, Patnaik MM. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv 9(19):5105-5117, 2025. e-Pub 2025. PMID: 40644618.
Azevedo RS, Fayad L, Kanagal-Shamanna R, Loghavi S, Hu S, Bueso-Ramos CE, Sasaki K, Abuasab T, Khawaja F, Goulart H, Abou Dalle I, Borthakur G, Pemmaraju N. Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation. Leuk Lymphoma 66(10):1947-1951, 2025. e-Pub 2025. PMID: 40440732.
Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
Azevedo RS, Wang SA, Swanson DM, Daver NG, Pemmaraju N, Kadia TM, Issa GC, Yilmaz M, Borthakur G, Senapati J, Jen WY, Short NJ, Ravandi F, Wang W, Fang H, Xu J, Patel KP, Tang G, Medeiros LJ, DiNardo CD, Loghavi S. CD123 expression and its correlation with mutation profile in acute myeloid leukaemia. Br J Haematol 207(4):1648-1652, 2025. e-Pub 2025. PMID: 41070667.
Goulart H, Garcia-Manero G, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qazilbash M, Rausch C, Llaurador Caraballo G, Pierce S, Pemmaraju N. A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma 66(9):1727-1730, 2025. e-Pub 2025. PMID: 40304131.
Bazinet A, Loghavi S, Wei Y, Bataller A, Sasaki K, Arani N, Darbaniyan F, Chien K, Hammond D, Bouligny I, Kanagal-Shamanna R, Thongon N, Tang G, Urrutia S, Kadia T, DiNardo C, Daver N, Short N, Issa G, Pemmaraju N, Jabbour E, Wang SA, Wang W, Borthakur G, Bueso-Ramos C, Ravandi F, Medeiros LJ, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol 43(24):2692-2699, 2025. e-Pub 2025. PMID: 40513054.
Arora S, Jen WY, Yilmaz M, Deshmukh I, Senapati J, Loghavi S, Issa GC, Short NJ, Kadia TM, DiNardo CD, Borthakur G, Jabbour J, Pemmaraju N, Andreeff M, Takahashi K, Bhalla K, Popat U, Shpall EJ, Oran B, Abbas HA, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation. Cancer 131(16):e70032, 2025. e-Pub 2025. PMID: 40782343.
Senapati J, Kantarjian HM, Kadia TM, Kekedjian J, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Short NJ, Yilmaz M, Jain N, Pemmaraju N, Abbas HA, Issa GC, Maiti A, Bravo GM, Deshmukh I, Shpall E, Kebriaei P, Popat U, Loghavi S, Thakral B, Tang G, Haddad FG, Alvarado Y, Manero GG, Ravandi F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16):e70028, 2025. e-Pub 2025. PMID: 40772501.
Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol 100(8):1365-1373, 2025. e-Pub 2025. PMID: 40401707.
Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia 39(8):2030-2034, 2025. e-Pub 2025. PMID: 40555734.
Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, Rodriguez-Meira A, Sui P, Olivier E, Jia Y, Gupta V, Fiskus W, Ramage CL, Zheng G, Schurer A, Gritsman K, Papapetrou EP, Bhalla K, Zhou D, Mead AJ, Rampal RK, Tyner JW, Abbas HA, Pemmaraju N, Tatarata QZ, Konopleva M. Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML. Blood 146(3):341-355, 2025. e-Pub 2025. PMID: 40163809.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110(7):1628-1633, 2025. e-Pub 2025. PMID: 39973365.
Pemmaraju N, Konopleva M, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat TL, Tosolini A, Gupta I, Lane AA. Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial. Leuk Lymphoma 66(7):1342-1345, 2025. e-Pub 2025. PMID: 40067964.
Chien KS, Curry JL, Pemmaraju N, Jain N. Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia. Am J Hematol 100(7):1240-1241, 2025. e-Pub 2025. PMID: 40062658.
Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Spencer Chapman M, Zhang L, Padilla J, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Ogata S, Hanache S, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Kanagal-Shamanna R, Bueso-Ramos C, Nakada D, Al-Atrash G, Molldrem J, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nat Genet 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
Pemmaraju N, Yu J, Vasudevan A, Qureshi H, Braunstein E, Chojecki A. Treatment patterns and blood count control in 10,112 patients with polycythemia vera. Expert Rev Hematol 18(7):529-536, 2025. e-Pub 2025. PMID: 40512071.
Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis. Clin Cancer Res 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, Abbas HA, Arani N, DiNardo CD, Borthakur G, Pemmaraju N, Oran B, Shpall E, Popat U, Champlin R, Pierce S, Arora S, Issa G, Yilmaz M, Patel K, Takahashi K, Montalban-Bravo G, Hammond D, Haddad FG, Ravandi F, Kantarjian HM, Daver NG. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms. Haematologica 110(6):1304-1315, 2025. e-Pub 2025. PMID: 39665206.
Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia TM, Borthakur G, Daver N, Short NJ, Jain N, Issa GC, Haddad F, Hammond D, Chien K, Tang G, Thakral B, Montalban-Bravo G, Pemmaraju N, Bazinet A, Swaminathan M, Pierce S, Abbas HA, Reville P, Popat U, Shpall E, Champlin R, Jabbour E, Ravandi F, Kantarjian HM, DiNardo CD. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies. Am J Hematol 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clin Lymphoma Myeloma Leuk 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA. Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. Blood Neoplasia 2(2):100086, 2025. e-Pub 2025. PMID: 40453135.
Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer 131(8):e35840, 2025. e-Pub 2025. PMID: 40193193.
Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
Nahmod KA, Miranda RN, Vega F, Thakral B, Pemmaraju N, Montalban-Bravo G, Loghavi S, Jelloul FZ, Wang W, Wang S, Muzzafar T, Patel K, Bueso-Ramos CE, Medeiros LJ, Kanagal-Shamanna R. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review. Leuk Lymphoma 66(4):764-772, 2025. e-Pub 2025. PMID: 39704386.
DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
Wei Q, Toruner GA, Thakral B, Patel KP, Pemmaraju N, Wang SA, Kanagal-Shamanna R, Tang G, Issa GC, Loghavi S, Medeiros LJ, DiNardo C. Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic Leukemia. Genes (Basel) 16(3), 2025. e-Pub 2025. PMID: 40149468.
Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, Ferrajoli A, Sasaki K, Alvarado Y, Pemmaraju N, Senapati J, Garris R, Ravandi F, Jabbour E. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
Pemmaraju N, Loghavi S. Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement. Blood 145(8):898, 2025. e-Pub 2025. PMID: 39976942.
Kharfan-Dabaja MA, Lane AA, Pemmaraju N. How I treat blastic plasmacytoid dendritic cell neoplasm. Blood 145(6):567-576, 2025. e-Pub 2025. PMID: 39374520.
Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell CE, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores LB, Loghavi S, DiNardo C, Su X, Rampal RK, Bhalla KN. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2025. e-Pub 2025. PMID: 39561280.
Yu J, Gayle J, Rosenthal N, Brown H, Braunstein E, Pemmaraju N. Resource utilization and inpatient hospitalization costs associated with thromboembolic events among patients with polycythemia vera. Oncologist 30(2), 2025. e-Pub 2025. PMID: 40037619.
Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39(2):524-528, 2025. e-Pub 2025. PMID: 39551874.
Pemmaraju N, Somervaille TCP, Palandri F, Harrison C, Komrokji RS, Perkins A, Ayala Diaz RM, Lavie D, Tomita A, Feng Y, Qin Q, Harb J, Polepally AR, Potluri J, Garcia JS. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. Blood Neoplasia 2(1):100056, 2025. e-Pub 2025. PMID: 40454409.
Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, Wierda W, Kadia TM, Daver NG, DiNardo CD, Short NJ, Jain N, Ferrajoli A, Kornblau S, Yilmaz M, Ohanian M, McCue D, Burger J, Hammond D, Patel K, Issa GC, Pemmaraju N, Sasaki K, Maiti A, Abbas HA, Chien K, Takahashi K, Haddad F, Bose P, Masarova L, Montalban-Bravo G, Swaminathan M, Brandt M, Pierce S, Garcia-Manero G, Ravandi F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1):e35662, 2025. e-Pub 2025. PMID: 39584789.
Park, GS, Atluri, H, DiNardo, C, Guillroy, B, Horak, J, Apostolidou, E, Buni, M, Montalban Bravo, G, Pemmaraju, N. Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies. Leukemia Research Reports 23, 2025. e-Pub 2025. PMID: 39691506.
Park GS, Atluri H, DiNardo CD, Guillroy B, Horak J, Apostolidou E, Buni M, Bravo GM, Pemmaraju N. Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report. Leuk Res Rep 23:100485, 2025. e-Pub 2025. PMID: 39691506.
Bashir Q, Konopleva M, Abueg G, Ramdial J, Hosing C, Srour SA, Alousi A, Popat UR, Nieto Y, Alatrash G, Champlin RE, Shpall EJ, Qazilbash M, Pemmaraju N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leuk Res Rep 24:100518, 2025. e-Pub 2025. PMID: 40612021.
Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel AB. Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. Leuk Res Rep 24:100541, 2025. e-Pub 2025. PMID: 40917153.
Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract 20(12):1637-1644, 2024. e-Pub 2024. PMID: 39013130.
Urrutia S, Kantarjian HM, Ravandi-Kashani F, Bueso-Ramos C, Kanagal-Shamanna R, Jabbour E, Montalban-Bravo G, Short NJ, Daver N, Borthakur G, Dinardo CD, Kadia TM, Masarova L, Bose P, Pemmaraju N, Garcia-Manero G, Sasaki K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol 17(1):112, 2024. e-Pub 2024. PMID: 39548557.
Phan, L, Jabbour, EJ, Antonoff, MB, Jain, N, Lin, P, Moran, C, Pemmaraju, N. Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia. Journal of Immunotherapy and Precision Oncology 7(4):314-316, 2024. e-Pub 2024. PMID: 39524462.
Jen WY, Jabbour E, Short NJ, Issa GC, Haddad FG, Jain N, Pemmaraju N, Daver NG, Masarova L, Borthakur G, Chien K, Garris R, Kantarjian HM. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol 99(11):2229-2232, 2024. e-Pub 2024. PMID: 39194286.
Short NJ, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
Phan L, Jabbour E, Antonoff MB, Jain N, Lin P, Moran C, Pemmaraju N. Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia. J Immunother Precis Oncol 7(4):314-316, 2024. e-Pub 2024. PMID: 39524462.
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, Dohner K, Ellis M, Gangat N, Garcia JS, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison C, Hexner EO, Hobbs GS, Kiladjian JJ, Koschmieder S, Kroger N, Kuykendall AT, Loscocco GG, Mascarenhas J, Masarova L, Mesa R, Mora B, Odenike O, Oh ST, Pardanani A, Patel A, Pemmaraju N, Rambaldi A, Rampal R, Sirhan S, Szuber N, Talpaz M, Vachhani PJ, Vannucchi AM, Barbui T. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood 144(17):1813-1820, 2024. e-Pub 2024. PMID: 39116296.
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma 65(9):1344-1349, 2024. e-Pub 2024. PMID: 38696743.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
Dhakal, P, Sy, M, Sutamtewagul, G, Mou, E, Yu, N, Pemmaraju, N. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting. Journal of Immunotherapy and Precision Oncology 7(3):205-209, 2024. e-Pub 2024. PMID: 39219995.
Dhakal P, Sy M, Sutamtewagul G, Mou E, Yu N, Pemmaraju N. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting. J Immunother Precis Oncol 7(3):205-209, 2024. e-Pub 2024. PMID: 39219995.
Urrutia S, Bose P, Alvarado Y, Borthakur G, Ravandi F, Daver N, Pemmaraju N, Jabbour E, Takahashi K, Kadia T, DiNardo C, Kornblau S, Kanagal-Shamanna R, Huang X, Bodden K, Kantarjian H, Garcia-Manero G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2):100008, 2024. e-Pub 2024. PMID: 40454402.
Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Chapman MS, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Shamanna RK, Ramos CB, Nakada D, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 38826462.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Khan F, Hashmi F, Ghahramanyan N, Baloyan E, Tamamyan G, Konopleva M, Pemmaraju N, Voskanyan A. Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. Oncology (Williston Park) 38(3):104-106, 2024. e-Pub 2024. PMID: 38517410.
Montalban-Bravo G, Jabbour E, Borthakur G, Kadia T, Ravandi F, Chien K, Pemmaraju N, Hammond D, Dong XQ, Huang X, Schneider H, John R, Kanagal-Shamana R, Loghavi S, Kantarjian H, Garcia-Manero G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol 204(3):898-909, 2024. e-Pub 2024. PMID: 37946611.
Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2024. PMID: 38086946.
Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Minana L, Thompson JE, Konopleva MY, Sloss CM, Watkins K, Bedse G, Du Y, Malcolm KE, Zweidler-McKay PA, Kantarjian HM. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol 25(3):388-399, 2024. e-Pub 2024. PMID: 38423051.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927-935, 2024. e-Pub 2024. PMID: 38113472.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R, Investigators RT. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med 390(8):723-735, 2024. e-Pub 2024. PMID: 38381675.
Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv 8(3):591-602, 2024. e-Pub 2024. PMID: 38052038.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen CA, Angelucci E, Vinti L, Mughal TI, Pawlowska AB. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients. EJHaem 5(1):61-69, 2024. e-Pub 2024. PMID: 38406504.
Andanamala, H, Pemmaraju, N, Al-Juhaishi, T. Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 22, 2024. e-Pub 2024. PMID: 39563865.
Andanamala H, Pemmaraju N, Al-Juhaishi T. Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience. Leuk Res Rep 22:100486, 2024. e-Pub 2024. PMID: 39563865.
Sasaki K, Ravandi F, DiNardo C, Welch MA, Kadia T, Kantarjian H. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 23(12):905-910, 2023. e-Pub 2023. PMID: 37730483.
Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK. Moving toward disease modification in polycythemia vera. Blood 142(22):1859-1870, 2023. e-Pub 2023. PMID: 37729609.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
He J, Garcia MB, Connors JS, Nunez CA, Quesada AE, Gibson A, Roth M, Cuglievan B, Pemmaraju N, McCall D. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm. J Pediatr Hematol Oncol 45(8):e1001-e1004, 2023. e-Pub 2023. PMID: 37661300.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J 13(1):148, 2023. e-Pub 2023. PMID: 37735426.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for =1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
Harrold E, Latham A, Pemmaraju N, Lieu CH. Early-Onset GI Cancers: Rising Trends, Genetic Risks, Novel Strategies, and Special Considerations. Am Soc Clin Oncol Educ Book 43:e398068, 2023. e-Pub 2023. PMID: 37235819.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, Valone F, Gupta S. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol 102(3):571-581, 2023. e-Pub 2023. PMID: 36637474.
Boyiadzis M, Desai P, Daskalakis N, Donnellan W, Ferrante L, Goldberg JD, Grunwald MR, Guttke C, Li X, Perez-Simon JA, Salamero O, Tucker T, Xu X, Yang J, Pemmaraju N, Alonso-Dominguez JM. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clin Transl Sci 16(3):429-435, 2023. e-Pub 2023. PMID: 36564917.
Pagano L, Zinzani PL, Pileri S, Quaglino P, Cuglievan B, Berti E, Pemmaraju N, Onida F, Willemze R, Orfao A, Barosi G. Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel. Hemasphere 7(3):e841, 2023. e-Pub 2023. PMID: 36844178.
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Collins M, Sweeney S, Busquet J, Rathore A, Deng Q, Green M, Grant S, Demo S, Choudhary G, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett G, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Komblau S, Daver N, Naqvi K, Short N, Garcia-Manero G, Tiziani S, Verma A. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq, 2023. e-Pub 2023. PMID: 36865338.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood 141(6):567-578, 2023. e-Pub 2023. PMID: 36399715.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol 146(6):523-530, 2023. e-Pub 2023. PMID: 37699357.
Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol 97(12):1599-1606, 2022. e-Pub 2022. PMID: 36117258.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi S. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol 35(11):1677-1683, 2022. e-Pub 2022. PMID: 35690645.
Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Pemmaraju N, Harrison C, Gupta V, Verstovsek S, Scott B, Oh ST, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Mesa R, Buckley S, Roman-Torres K, Vannucchi A, Yacoub A. Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHaem 3(4):1346-1351, 2022. e-Pub 2022. PMID: 36467816.
Venugopal S, Borthakur G, Daver N, DiNardo CD, Pemmaraju N, Short NJ, Abbas HA, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv 6(19):5546-5549, 2022. e-Pub 2022. PMID: 35201293.
Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S204, 2022. e-Pub 2022. PMID: 36163747.
Abuasab T, Senapati J, Kadia T, Ravandi F, DiNardo C, Pemmaraju N, Ohanion M, Alvarado Y, Kantarjian H, Borthakur G. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)- Based Regimen. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S235-S236, 2022. e-Pub 2022. PMID: 36163808.
Abuasab T, Alvarado Y, Issa G, Islam R, James N, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Pemmaraju N, Bravo GM, Pierce S, DiNardo C, Kadia T, Daver N, Konopleva M, Garcia-Manero G, Ravandi F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S237, 2022. e-Pub 2022. PMID: 36163813.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Abuasab T, Mohamed SF, Biostatistics HH, Biostatistics XW, Sasaki K, Yilmaz M, Kadia T, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Kantarjian H, Garcia-Manero G, Takahashi K. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clin Lymphoma Myeloma Leuk 22 Suppl 2:S243, 2022. e-Pub 2022. PMID: 36163827.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S244-S245, 2022. e-Pub 2022. PMID: 36163828.
Pemmaraju N, Konopleva M, Sweet K, Stein A, Vasu S, Rizzieri D, Wang ES, Kantarjian H, Brooks C, Mughal T, Lane A. AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S254, 2022. e-Pub 2022. PMID: 36163847.
Chien K, Kim K, Li Z, Shamanna RK, Ong F, Bravo GM, Kadia T, Jabbour E, Pemmaraju N, Hammond D, Short N, Ravandi F, Alvarado Y, Pierce S, Dong XQ, Kantarjian H, Garcia-Manero G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S311, 2022. e-Pub 2022. PMID: 36163957.
Kim K, Ong F, Li Z, Shamanna RK, Bravo GM, Kadia T, Jabbour E, Pemmaraju N, Hammond D, Short N, Ravandi F, Alvarado Y, Pierce S, Dong XQ, Kantarjian H, Garcia-Manero G, Chien K. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
Ong F, Kim K, Shamanna RK, DiNardo C, Takahashi K, Kadia T, Jabbour E, Short NJ, Hammond D, Pemmaraju N, Pierce SA, Bravo GM, Kantarjian H, Garcia-Manero G, Chien KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH): A Single Institution Experience. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S319, 2022. e-Pub 2022. PMID: 36163972.
Venugopal S, Kantarjian H, Maiti A, Short NJ, Montalban-Bravo G, Alvarado Y, Chien K, Kanagal-Shamanna R, Pemmaraju N, Daver N, Kadia T, Borthakur G, Jabbour E, Garcia-Manero G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clin Lymphoma Myeloma Leuk 22 Suppl 2:S321, 2022. e-Pub 2022. PMID: 36163977.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. e-Pub 2022. PMID: 36164003.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. e-Pub 2022. PMID: 36164004.
Pemmaraju N, Kuykendall A, Kremyanskaya M, Ginzburg Y, Ritchie E, Gotlib J, Gerds A, Palmer J, Valone F, O'Connor P, Modi N, Gupta S, Hoffman R, Verstovsek S. MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S338-S339, 2022. e-Pub 2022. PMID: 36164011.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1(10):EVIDoa2200034, 2022. e-Pub 2022. PMID: 38319837.
Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol 40(26):3032-3036, 2022. e-Pub 2022. PMID: 35820082.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):2161-2170, 2022. e-Pub 2022. PMID: 35442137.
Wilson NR, Jain P, Gomez JA, Lu H, Pemmaraju N. Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome. Leuk Res 120:106909, 2022. e-Pub 2022. PMID: 35820269.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
El Hussein S, Yabe M, Wang W, Pemmaraju N, Loghavi S, Jelloul FZ, Fang H, Medeiros LJ, Burack WR, Evans AG, Liesveld JL, Bennett JM. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. EJHaem 3(3):954-957, 2022. e-Pub 2022. PMID: 36051075.
Wang W, Xu J, Khoury JD, Pemmaraju N, Fang H, Miranda RN, Yin CC, Hussein SE, Jia F, Tang Z, Hu S, Konopleva M, Medeiros LJ, Wang SA. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884435.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol 9(6):e434-e444, 2022. e-Pub 2022. PMID: 35576960.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. e-Pub 2022. PMID: 35061885.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol 40(15):1671-1680, 2022. e-Pub 2022. PMID: 35180010.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, Bah I, Wang W, Konoplev S, Medeiros LJ, Pemmaraju N, Khoury JD, Wang SA. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343-1350, 2022. e-Pub 2022. PMID: 35279700.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 2022. e-Pub 2022. PMID: 35484100.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res 115:106809, 2022. e-Pub 2022. PMID: 35220060.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Wilson NR, Pemmaraju N. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Pharmacother 23(4):431-438, 2022. e-Pub 2022. PMID: 35060807.
Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, Taylor J, Kim SS, Griffin GK, Ghandi M, Li J, Li YY, Angelot-Delettre F, Biichle S, Seiler M, Buonamici S, Lovitch SB, Louissaint A Jr, Morgan EA, Jardin F, Piccaluga PP, Weinstock DM, Hammerman PS, Yang H, Konopleva M, Pemmaraju N, Garnache-Ottou F, Abdel-Wahab O, Koeffler HP, Lane AA. Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discov 12(2):522-541, 2022. e-Pub 2022. PMID: 34615655.
Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
Gerds AT, Yu J, Scherber RM, Paranagama D, Kish JK, Visaria J, Singhal M, Verstovsek S, Pemmaraju N. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes. Acta Haematol 145(4):448-453, 2022. e-Pub 2022. PMID: 35008087.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
Abla D, Abboud MR, Noun D, Tarek N, Pemmaraju N. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review. Leuk Res Rep 17:100313, 2022. e-Pub 2022. PMID: 35462725.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957-2960, 2021. e-Pub 2021. PMID: 34350483.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):3402-3410, 2021. e-Pub 2021. PMID: 34380367.
Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, Tang Z, Alswailmi O, Bhalla KN, Qazilbash MH, Konopleva M, Khoury JD. Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34884997.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, Milne P, Collin M, Beird HC, Taylor J, Patnaik MM, Cargo CA, Somervaille TCP, Wiseman DH. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia 35(11):3299-3303, 2021. e-Pub 2021. PMID: 33833384.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768-2778, 2021. e-Pub 2021. PMID: 34043428.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol 96(8):1000-1007, 2021. e-Pub 2021. PMID: 33991360.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327.e6, 2021. e-Pub 2021. PMID: 33551345.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer 127(8):1246-1259, 2021. e-Pub 2021. PMID: 33270904.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, Li S, Pemmaraju N, Nguyen T, Medeiros LJ, Wang SA. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 106(4):1047-1055, 2021. e-Pub 2021. PMID: 32241840.
Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma 62(4):909-917, 2021. e-Pub 2021. PMID: 33283580.
Pemmaraju N. Targeting the p-D-C: easy as C-D-1-2-3?. Blood 137(10):1277-1278, 2021. e-Pub 2021. PMID: 33704391.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2021. PMID: 32561839.
Chen NC, Borthakur G, Pemmaraju N. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leuk Lymphoma 62(3):528-537, 2021. e-Pub 2021. PMID: 33161793.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
Pemmaraju N, Wilson NR, Clementi Doan T, Qiao W, Peterson SK, Zoeller V, Schorr A, Verstovsek S. Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. Leuk Lymphoma:1-8, 2021. e-Pub 2021. PMID: 33749512.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 34238762.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol 192(3):667-671, 2021. e-Pub 2021. PMID: 33238033.

Review Articles

Pemmaraju N, Fan Q, Ronnebaum S, Punja S, Kamar J, Cherepanov D, Hernandez L, Pettit K. Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review. Expert Rev Hematol:1-19, 2026. e-Pub 2026. PMID: 42236165.
Goulart H, Masarova L, Pemmaraju N, Bose P. A pharmacological profile of pacritinib for the treatment of myelofibrosis. Expert Rev Clin Pharmacol 19(5):409-418, 2026. e-Pub 2026. PMID: 41949314.
Haddad, FG, Croden, J, Sasaki, K, Issa, GC, Pemmaraju, N, Kantarjian, HM, Jabbour, EJ. Management of Chronic Myeloid Leukemia During Pregnancy. Clinical Lymphoma, Myeloma and Leukemia 26(1):19-25, 2026. e-Pub 2026. PMID: 40883153.
Azevedo RS, Nooruddin Z, Bhatia S, Finn L, Davis C, Alsfeld LC, Subbiah S, Norkin M, Ulrickson M, De La Fuente A, Larson ML, Budak-Alpdogan T, Pemmaraju N. The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm. Expert Opin Biol Ther 26(1):15-24, 2026. e-Pub 2026. PMID: 41447337.
Lane AA, Papayannidis C, Angelucci E, McCloskey J, Schiller GJ, de la Fuente Burguera A, Montesinos P, Nagarwala Y, Herling M, Mannis G, Pemmaraju N. Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Leuk Lymphoma 66(14):2569-2577, 2025. e-Pub 2025. PMID: 41134616.
Haddad FG, Croden J, Sasaki K, Issa GC, Pemmaraju N, Kantarjian H, Jabbour E. Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm. Clin Lymphoma Myeloma Leuk, 2025. e-Pub 2025. PMID: 40883153.
Kuhn MWM, Pemmaraju N, Heidel FH. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms. Leukemia 39(8):1824-1837, 2025. e-Pub 2025. PMID: 40374809.
Polverelli N, Hernandez-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M, Robin M, Sockel K, Ruggeri A, Sanchez-Ortega I, Arber DA, Arcaini L, Duarte FB, Battipaglia G, Chalandon Y, Ciceri F, Cross NCP, Drozd-Sokolowska J, Funke V, Gagelmann N, Gangat N, Gotlib J, Guglielmelli P, Harrison C, Hobbs G, Jain T, Khoury JD, Kiladjian JJ, Kroger N, Malcovati L, Martino M, Mesa R, Orazi A, Padron E, Palandri F, Passamonti F, Patnaik MM, Pemmaraju N, Radia DH, Reiter A, Russo D, Scheid C, Tefferi A, Vannucchi AM, Wiseman DH, Yakoub-Agha I, McLornan DP. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood 145(22):2561-2573, 2025. e-Pub 2025. PMID: 40106773.
Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo CD, Rausch CR, Ravandi F, Kadia TM. Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. Blood Cancer Discov 6(1):23-37, 2025. e-Pub 2025. PMID: 39565177.
Masarova L, Mascarenhas J, Rampal R, Hu W, Livingston RA, Pemmaraju N. Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer 131(1):e35661, 2025. e-Pub 2025. PMID: 39616447.
Pemmaraju N. BPDCN: state of the art. Hematology Am Soc Hematol Educ Program 2024(1):279-286, 2024. e-Pub 2024. PMID: 39644068.
Patel AB, Masarova L, Mesa RA, Hobbs G, Pemmaraju N. Polycythemia vera: past, present and future. Leuk Lymphoma 65(11):1552-1564, 2024. e-Pub 2024. PMID: 38871488.
Swaminathan M, Jain A, Choi SD, Pemmaraju N. Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?. Expert Rev Hematol 17(11):769-780, 2024. e-Pub 2024. PMID: 39344987.
Phan L, Hammond D, Wilson NR, Groarke EM, Patnaik MM, Pemmaraju N. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field. Leuk Lymphoma 65(9):1245-1257, 2024. e-Pub 2024. PMID: 38770970.
Jen WY, Konopleva M, Pemmaraju N. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer 130(13):2260-2271, 2024. e-Pub 2024. PMID: 38620053.
Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian JJ, Pemmaraju N. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. Br J Haematol 205(1):48-60, 2024. e-Pub 2024. PMID: 38853641.
Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma 65(5):548-559, 2024. e-Pub 2024. PMID: 38391126.
Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, Mughal T, Mohty M, Angelucci E. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk 24(4):e130-e137, 2024. e-Pub 2024. PMID: 38267355.
Pemmaraju N, Garcia JS, Perkins A, Harb JG, Souers AJ, Werner ME, Brown CM, Passamonti F. New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X(L) /BCL-2 inhibition with navitoclax. Cancer 129(22):3535-3545, 2023. e-Pub 2023. PMID: 37584267.
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma 64(6):1063-1081, 2023. e-Pub 2023. PMID: 37081809.
Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol 21(5):257-264, 2023. e-Pub 2023. PMID: 37145496.
Babakhanlou R, Verstovsek S, Pemmaraju N, Rojas-Hernandez CM. Secondary erythrocytosis. Expert Rev Hematol 16(4):245-251, 2023. e-Pub 2023. PMID: 36927204.
Polverelli N, Hernandez-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kroger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol 10(1):e59-e70, 2023. e-Pub 2023. PMID: 36493799.
Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. e-Pub 2022. PMID: 36383908.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brummendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol 40(4):491-504, 2022. e-Pub 2022. PMID: 35368098.
Adimora IJ, Wilson NR, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Cancer 128(16):3019-3026, 2022. e-Pub 2022. PMID: 35726525.
Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Dohner K, Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 128(13):2420-2432, 2022. e-Pub 2022. PMID: 35499819.
Bole-Richard E, Pemmaraju N, Cael B, Daguindau E, Lane AA. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 14(9), 2022. e-Pub 2022. PMID: 35565416.
Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2022. PMID: 34840087.
Wilson NR, Bover L, Konopleva M, Han L, Neelapu S, Pemmaraju N. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 63(1):19-30, 2022. e-Pub 2022. PMID: 34486917.
Wilson NR, Pemmaraju N. How to Treat Adult Acute Myeloid Leukemia: An Evolving Paradigm. JACC CardioOncol 3(5):747-751, 2021. e-Pub 2021. PMID: 34988486.
Mouhayar EN, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome. JACC CardioOncol 3(5):752-755, 2021. e-Pub 2021. PMID: 34988487.
Patnaik MM, Mughal TI, Brooks C, Lindsay R, Pemmaraju N. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leuk Lymphoma 62(11):2568-2586, 2021. e-Pub 2021. PMID: 33999767.
DiPippo AJ, Wilson NR, Pemmaraju N. Targeting CD123 in BPDCN: an emerging field. Expert Rev Hematol 14(11):993-1004, 2021. e-Pub 2021. PMID: 34607517.
Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Clin Lymphoma Myeloma Leuk 21(11):734-740, 2021. e-Pub 2021. PMID: 34226167.
Lee SS, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. J Immunother Precis Oncol 4(3):117-128, 2021. e-Pub 2021. PMID: 35663101.
El Hussein S, Wang SA, Pemmaraju N, Khoury JD, Loghavi S. Chronic Myelomonocytic Leukemia: Hematopathology Perspective. J Immunother Precis Oncol 4(3):142-149, 2021. e-Pub 2021. PMID: 35663104.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18(5):313-319, 2021. e-Pub 2021. PMID: 33723371.
Pemmaraju N, Chen NC, Verstovsek S. Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 35(2):409-429, 2021. e-Pub 2021. PMID: 33641877.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.

Professional Educational Materials

Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes, 2024.
Pemmaraju N, Konopleva M. Focus on Rare Blood Cancers: Novel Targeted Therapies and New Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in 2020 and Beyond.

Editorials

Brown SA, Yang EH, Reza N, Guha A, Ismail-Khan R, Pemmaraju N, Fradley MG, Lopez-Mattei J. #JACCCardioOnc: Evolution of a Dedicated Social Media Strategy for JACC: CardioOncology. JACC CardioOncol 3(3):461-464, 2021. PMID: 34604810.
Pemmaraju N. A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic. Cancer 127(16):2867-2869, 2021. PMID: 33891316.
Pemmaraju N. Rare Blood Cancers in 2021: Importance of Continued Exchange of Ideas. J Immunother Precis Oncol 4(3):115-116, 2021. PMID: 35663105.

Abstracts

Pemmaraju N, Garcia J, Potluri J, Sun Y, Harb J, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy. Cancer Research 82(12_Supplement), 2022. e-Pub 2022.
Pemmaraju N, Scott BL, Savona MR, Oh ST, Harrison C, Vannucchi AM, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Gupta V, Mesa RA, Buckley S, Roman-Torres K, Verstovsek S, Yacoub AA. Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF). Journal of Clinical Oncology 40(16_Suppl), 2022. e-Pub 2022.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SA, Villarreal J, Qazilbash MH, Konopleva M, Kantarjian H. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Martinelli G, Todisco E, Lane AA, Acuña-Cruz E, Deconinck E, Wang ES, Sweet K, Rizzieri DA, Marconi G, Mazzarella L, DeAngelo DJ, Montesinos P, Gigli F, Erba HP, Konopleva M, Kantarjian H, Walter RB, Aribi A, Lebon D, Levy MY, Sloss CM, Malcolm KE, Zweidler-McKay PA, Daver N. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Bhalla KN, Daver N, Wilson NR, Fiskus WC, Ravandi F, Garcia-Manero G, Kadia TM, DiNardo CD, Jabbour EJ, Burger JA, Short NJ, Alvarado Y, Jain N, Masarova L, Verstovsek S, Issa GC, Qiao W, Khoury JD, Pierce SA, Miller D, Konopleva M, Kantarjian H, Borthakur G. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Kantarjian H, Sweet K, Wang ES, Lane AA, Ali H, Stein AS, Yacoub A, Rizzieri DA, Vasu S, Gupta V, Lee S, Schiller GJ, Foran JM, Taparia MS, Rosenblat TL, Walter RB, Sieminski D, Anant M, Patnaik MM, Mughal TI, Konopleva M. Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood 138(Supp 1), 2021. e-Pub 2021.
Pemmaraju N, Konopleva M, Sweet K, Stein AS, Vasu S, Rizzieri DA, Wang ES, Kantarjian H, Brooks CL, Mughal TI, Lane AA. Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. Blood 138(Supp 1), 2021. e-Pub 2021.

Book Chapters

Kale, BJ, Wilson, NR, Pemmaraju, N. Chimeric Antigen Receptor Therapy in Acute Myeloid Leukemia, 205-216, 2023.
Pemmaraju, N. Blastic plasmacytoid dendritic cell neoplasm. In: 5th Edition of the WHO Classification of Tumours (“WHO Blue Books”). 5th. International Agency for Research on Cancer (IARC).

Letters to the Editor

Jabbour E, Goulart H, Sasaki K, Rausch CR, Jain N, Kadia TM, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Montalban-Bravo G, Garcia-Manero G, Hammond D, Swaminathan M, Hachem M, Khouri R, Ohanian M, Garris R, Short NJ, Kantarjian HM. Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis. Am J Hematol 101: 1729-1736, 2026.
Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Hachem M, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E. Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Am J Hematol 101: 1717-1722, 2026.
Senapati J, Garcia-Manero G, DiNardo CD, Deshmukh I, Borthakur G, Kadia TM, Jabbour E, Short NJ, Abbas HA, Pemmaraju N, Jain N, Haddad FG, Issa GC, Maiti A, Shpall E, Popat U, Loghavi S, Tang G, Yilmaz M, Alvarado Y, Montalban-Bravo G, Ravandi F, Kantarjian HM, Daver NG. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone Marrow Transplant 60: 910-913, 2025.
Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning J, Kantarjian H, Konopleva MY. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Blood Cancer J 15: 52, 2025.
Kawedia JD, Rausch CR, Liu X, Qiao W, Dinardo CD, Daver N, Borthakur G, Pemmaraju N, Reville P, Kontoyiannis DP, Short N, Konopleva M, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals. Am J Hematol 100: 740-743, 2025.
Mustafayev K, Yepez Guevara E, DiNardo CD, Jabbour E, Ghayas IC, Ratan R, Pemmaraju N, Torres HA. Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study. Leuk Res 147: 107597, 2024.
Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk 24: 732-735, 2024.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109: 2660-2664, 2024.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
Hu X, Ediriwickrema A, Saleem A, Tan B, Pemmaraju N, Mannis GN. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res 139: 107479, 2024.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99: 792-796, 2024.
Beird H, Yin CC, Khoury JD, Pierce S, Abbas HA, Zhao L, Skwarska A, Qazilbash M, Konopleva M, Futreal PA, Pemmaraju N. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7: 2000-2003, 2023.
Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98: E53-E56, 2023.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119: 106884, 2022.
Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 97: E62-E67, 2022.
El Hussein S, Wang W, Wang SA, Loghavi S, Wang X, Qiu L, Fang H, Medeiros LJ, Aung PP, Torres Cabala C, Jorgensen JL, Pemmaraju N, Khoury JD. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma 62: 3296-3299, 2021.
Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, Jabbour E, Kadia T, DiNardo C, Garcia-Manero G, Qazilbash M, Konopleva M, Kantarjian H. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood 138: 1373-1377, 2021.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106: 1988-1990, 2021.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol 96: E246-E249, 2021.
Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193: 1004-1008, 2021.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35: 1494-1499, 2021.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11: 60, 2021.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106: 894-898, 2021.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96: E50-E53, 2021.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11: 25, 2021.

Less

CV information above last modified July 31, 2026

Naveen Pemmaraju, M.D.

About Dr. Naveen Pemmaraju

In the News

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care

ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

ARCHIVED: Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Department of Leukemia

Division of Cancer Medicine

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson